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Hepatocellular carcinomaThe activity of theWnt pathway undergoes complex regulation to ensure proper functioning of this principal sig-
naling mechanism during development of adult tissues. The regulation may occur at several levels and includes
both positive and negative feedback loops. In the present study we employed one of such negative feedback
regulators, naked cuticle homolog 1 (Nkd1), to follow the Wnt pathway activity in the intestine and liver and
in neoplasia originated in these organs. Using lineage tracing in transgenic mice we localized Nkd1 mRNA to
the bottomparts of the small intestinal crypts and hepatocytes surrounding the central vein of the hepatic lobule.
Furthermore, in two mouse models of intestinal tumorigenesis, Nkd1 expression levels were elevated in tumors
when compared to healthy tissue.We utilized a collection of human intestinal polyps and carcinomas to conﬁrm
thatNKD1 represents a robust marker of neoplastic growth. In addition, expression analysis ofNKD1 in liver can-
cer showed that high expression levels of the gene distinguish a subclass of hepatocellular carcinomas related to
aberrant Wnt signaling. Finally, our results were conﬁrmed by bioinformatic analysis of large publicly available
datasets that included gene expression proﬁling and high-throughput sequencing data of human colon and
liver cancer specimens.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The Wnt pathway represents one of the principal signaling mecha-
nisms regulating development and tissue homeostasis in metazoan
species. In the adult organism, aberrantWnt signaling is involved in var-
ious diseases including cancer (reviewed in [1]). The centralmediator ofbacterial artiﬁcial chromosome;
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. This is an open access article underthe best studied so-called canonicalWnt pathway isβ-catenin, a protein
playing a dual role in cell adhesion and signaling (reviewed in [2]). In
the absence of an extracellular Wnt stimulus the β-catenin destruction
complex, which is composed of casein kinase 1 alpha (CK1α) and glyco-
gen synthase kinase 3 (GSK3), and scaffolding proteins adenomatous
polyposis coli (Apc) and axin/conductin, phosphorylates β-catenin on
the N-terminal serine/threonine residues. The phosphorylated protein
is ubiquitinylated and subsequently degraded by the proteasome.
Consequently, in unstimulated cell, the cytoplasmic levels ofβ-catenin re-
main low. Interaction ofWnt ligandwith the receptor complex comprised
of the Frizzled receptor and low-density lipoprotein receptor-related pro-
tein 5/6 (LRP5/6) co-receptor disrupts the function of the destruction
complex. Subsequently, β-catenin accumulates in the cytoplasm and in
the nucleus,where it associateswith transcription factors of the lymphoid
enhancer-binding factor/T-cell factor (LEF/TCF) family (further referred to
as TCFs). Since β-catenin contains a transactivation domain, the TCF-β-
catenin complexes act as bipartite transcriptional activators of the Wnt-
responsive genes, such as Axin2, c-Myc, CD44 or cyclin D1 (for more com-
prehensive survey about the Wnt signaling target genes refer to theWnt
signaling home page: http://web.stanford.edu/group/nusselab/cgi-bin/
wnt/target_genes).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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in mammalian body (reviewed in [3]). The single-layer epithelium of
the small intestine is formed by microscopic projections into the intes-
tinal lumen called villi, and invaginations into underlyingmesenchyme,
so-called crypts of Lieberkühn. Tissue homeostasis is maintained by
intestinal stem cells (ISCs) residing in the bottom part of the crypts.
ISCs divide asymmetrically, giving rise to fast-cycling transit amplifying
(TA) cells located above the stem cell zone. Descendants of TA cells
move up along the crypt/villus axis. At the crypt oriﬁce these cells
differentiate to generate specialized cell lineages of the gut that mainly
include absorptive enterocytes, mucus-secreting goblet cells, and
enteroendocrine cells producing hormones. Differentiated cells contin-
ue their movement up to the top of the villus, where they are extruded
to the intestinal lumen. The process of epithelial self-renewal is com-
pleted in 3–5 days. One exception from this scheme are Paneth cells.
The life span of these cells is 6–8 weeks. Furthermore, mature Paneth
cells do not migrate from the crypt but stay at the crypt bottom,
where they produce antibacterial cryptidins, defensins, and lysozyme
(reviewed in [4]). The tissue architecture of the colon reminds the
small intestine; however, it does not contain Paneth cells and its surface
is ﬂat without the extruding villi. ISCs, alternatively named according to
their slender appearance and localization in the lower portion of the
crypt as crypt base columnar (CBC) cells, can be recognized by ex-
pression of leucine-rich repeat containing G protein-coupled receptor
5 (Lgr5) [5]. Recently, several other markers of ISCs were discovered.
These include the tumor necrosis factor receptor family member Troy
[6], transcription regulator achaete-scute complex homolog 2 (Ascl2),
and an extracellular matrix glycoprotein, olfactomedin 4 (Olfm4) [7].
In addition, CBCs produce high levels of transmembrane ephrin type-B
receptor 2 (EphB2), whose expression declines in TA cells, and Paneth
cells are EphB2 negative [8].
A number of studies established the Wnt pathway as the main
constituent of the signaling network regulating ISCs pluripotency and
proliferation (reviewed in [9]). For example, the expression of stem
cell markers Ascl2, Lgr5 and Troy is governed by the canonicalWnt path-
way. Moreover, genetic disruption of genes encoding theWnt pathway
effectors Tcf4 [10,11] or β-catenin [12,13] is associated with demise of
intestinal crypts. Interestingly, Wnt/β-catenin signaling plays a key
role in the metabolic zonation of the liver (reviewed in [14]). To fulﬁll
its metabolic function, the liver tissue is organized into hepatic lobules,
hexagonal-shaped functional units of hepatic parenchyma composed of
15–25 cells. The hepatocytes in the center of the lobule are called
perivenous, since they surround a hepatic centrilobular vein. The
outer row of lobular hepatocytes line the portal space. These periportal
cells are in close contact with the so-called portal triad consisting of the
hepatic artery, portal vein and bile duct. Consequently, the periportal
hepatocytes receive a mixture of blood originating from both vessels.
The portocentrovenular axis of the lobule is the basis for the zonation
of the metabolic functions in the adult organ. Cells in different areas of
the hepatic lobule are not equal, but they express different genes in-
volved in themetabolismof carbohydrates, xenobiotics, bile production,
and detoxiﬁcation of ammonia. The perivenous hepatocytes contain nu-
clearβ-catenin and they display activeWnt signaling. TheWnt pathway
regulates genes encoding enzymes of ammonia detoxication and trans-
port. The genes include glutamine synthetase (GS/Glul), ornithine amino-
transferase (Oat), and leukocyte cell-derived chemotaxin-2 (Lect2). In
contrast, high Apc protein levels in the periportal hepatocytes suppress
theWnt pathway activity. This leads to production of a different set of en-
zymesmainly participating in ammonia, urea, and carbohydratemetabo-
lism such as glutaminase 2 (Gls2), arginase 1, and phosphoenolpyruvate
carboxykinase 1 (Pck1) [15].
Aberrant Wnt signaling is found in a multitude of solid tumors,
particularly in carcinoma of the colon and rectum [colorectal carcinoma
(CRC) [reviewed in [16]]. It is assumed that in the majority of sporadic
CRCs the “driver” mutation providing selective advantage to the
prospective cancer cell occurs in the APC tumor supressor [17,18]. Themutational changes inAPC lead toproduction of truncatedAPCpolypep-
tide that compromises proper functioning of the β-catenin destruction
complex (reviewed in [19]). The Wnt pathway might also be activated
by inactivating mutations in AXIN1 [20] or AXIN2 [21]. In addition, ap-
proximately 5% of CRCs contain oncogenic mutations in the CTNNB1
gene (this gene encodesβ-catenin) that alter regulatory amino acid res-
idues at the β-catenin N-terminus and stabilize the protein [22]. The
most common type of liver cancer is hepatocellular carcinoma (HCC).
The etiology of the disease is heterogeneous and is frequently linked
to hepatitis B virus (HBV) or hepatitis C virus (HCV) chronic infection
or to alcoholism-related cirrhosis (reviewed in [23]). Recently, several
studies performed gene expression proﬁling and/or high-throughput
DNA sequencing to identify themolecular subclasses of HCC or to detect
the driver mutations related to liver carcinogenesis [24,25]. Important-
ly, approximately one-half of HCCs display elevated expression levels of
genes activated by Wnt signaling, and oncogenic mutations in the
CTNNB1 gene are found in 20-30% of all HCCs. Analogically to CRC,
high levels of stabilized β-catenin and inappropriate transcriptional ac-
tivation of the TCF-β-catenin target genes is a hallmark of a signiﬁcant
portion of HCCs (reviewed in [26]).
In our previous studywe employed chromatin immunoprecipitation
in combination with DNA microarray analysis (so-called ChIP-on-chip)
to identify genes activated by aberrant Wnt/β-catenin signaling in
human CRC cells. One of the genes bound by the TCF4-β-catenin com-
plexeswasnaked cuticle homolog 1 (NKD1) [6]. Nkd1 is an evolutionarily
conserved feedback inhibitor of theWnt pathway [27]. It interacts with
dishevelled (Dvl1) and mediates degradation of this cytoplasmic Wnt
signal transducer [28]. Nkd1 reduces aberrantWnt signaling; neverthe-
less, in the absence the excessiveWnt signal, its function is less apparent
[29,30]. Simultaneous inactivation of both vertebrate paralogsNkd1 and
Nkd2 in themouse leads to only subtle alterations in the morphology of
cranial bones and slightly reduced litter size, but themice are otherwise
normal [31]. Based on these and other results mainly obtained in
zebraﬁsh [30], Angonin and Van Raay proposed that Nkd1 functions as
a “passive antagonist” that acts only when the Wnt signaling levels ex-
ceed some threshold [32].
In the present study,we analyzed theNkd1 expression pattern in adult
mouse gut and liver tissue. Using lineage tracing approaches in transgenic
animalswe show thatNkd1 expression is conﬁned to the areaswith active
Wnt signaling. Furthermore,Nkd1 transcriptionwas robustly increased in
tumors developed inmultiple intestinal neoplasia (Min) of mice or in hy-
perplastic crypts generated by conditional deletion of the Apc gene. Using
a panel of sporadic tumors of the colon we conﬁrmed that elevated ex-
pression of NKD1 marks neoplastic tissue. In hepatic neoplasia, high
NKD1mRNA levels, together with upregulation of AXIN2, EPHB2, and GS,
distinguish a class of HCCs with deregulated Wnt signaling.
2. Materials and methods
2.1. Experimental animals
Apc+/Min [33,34], Lgr5-EGFP- IRES-CreERT2 [5], Rosa26R [35], and
Rosa26R-EYFP [36] mice were purchased from the Jackson Laboratory
(Bar Harbor, ME). ApccKO/cKO [37] mice were obtained from the Mouse
Repository (National Cancer Institute, Frederick, MD). Villin-CreERT2
mice [38] were kindly provided by Sylvia Robine (Institut Curie, Paris,
France). Animals were housed and handled according to the guide-
lines approved by the institutional committee. Tamoxifen (Sigma-
Aldrich, St. Louis, MO) administration was done by intraperitoneal
injection of 1 mg of the compound dissolved in 0.1 ml of corn oil.
DNA from tail clippings was used for genotyping. Tissue samples
were digested in Proteinase K solution (Thermo Fisher Scientiﬁc,
Waltham, MA) and precipitated using ethanol; pellets were dis-
solved in 20 μl of TE buffer (10 mM Tris-HCl, 1 EDTA, pH 8) and
1 μl was used for PCR performed with DreamTaq PCR Master Mix
(Thermo Fisher Scientiﬁc, Waltham, MA).
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The Nkd1-CreERT2 bacterial artiﬁcial chromosome (BAC) transgenic
construct was generated using homologous recombination in bacteria
according to the previously published protocol [39]. The BAC clone
RP23-301 N2 was purchased from imaGenes (Berlin, Germany); a con-
struct containing CreERT2 cDNA was kindly provided by M. Cepko via
Addgene. The adapters “a” (5′-TCCTTTCTTTCCGGCTCCCGCCGCCGCCGC
CGCGCGCGATGTGCCCGCAGCCatgtccaatttactgaccgtac- 3′; the Nkd1-
speciﬁc sequence is capitalized, the part complementary to the CreERT2
expression cassette is given in lowercase) and “b” (5′-AGAGACCAAGTT
CTCCGGAGTAGGGGCTGGCGACTAGAGGAAGGCGCAAGTGGCGGCCGC
TCTAGAACTAGTG- 3′) were derived from the sequence of theNkd1 sec-
ond exon. The adapters were employed for PCR ampliﬁcation, the prod-
uct was puriﬁed from agarose gel and electroporated into the E. coli
strain EL250 harboring the BAC clone. Bacterial clones containing cor-
rectly recombined BACs were veriﬁed by PCR. Isolated recombinant
BAC DNA was linearized and used for pronuclear injection of fertilized
eggs (C57Bl/6 J background). Two Nkd1-CreERT2 transgenic founder
lineswere produced using the service of the Transgenic Unit of the Insti-
tute of Molecular Genetics (IMG). Two lines exhibited a virtually identi-
cal pattern of the Cre recombinase activity.
2.3. X-gal staining, immunohistochemistry, antibodies, and periodic
acid-Schiff (PAS) staining
Mouse tissues were stained with X-gal (Amresco, Solon, OH) prior
to parafﬁn embedding. Tissue processing and staining was performed
as described previously [5]. Slides were immersed in a steam bath
(20min, 10mMcitrate buffer, pH 6) for antigen retrieval. The following
rabbit polyclonal antibodies were used for immunohistochemistry:
anti-chromogranin A (cat. No. ab15160, Abcam, Cambridge, UK), anti-
lysozyme (cat. No. A0099, Dako, Glostrup, DK), anti-glutamine synthe-
tase (cat. No. ab73593, Abcam). PAS (Diapath, Martinengo, IT) staining
was performed according to the standard protocol provided by the sup-
plier. Slides were counterstained using either hematoxylin (Penta,
Prague, CZ) or nuclear fast red (Diapath, Martinengo, IT).
2.4. RNA probes and in situ hybridization (ISH)
Both sense and antisense RNA probes were derived from the follow-
ing regions of the analyzed genes: Axin2 (accession: NM_015732.4), nu-
cleotides (nt) 2069-2938; Nkd1 (NM_001163660.1), nt 509-944. DNA
fragments encompassing the indicated regions were subcloned into
pBluescript SK II (Stratagene, La Jolla, CA). The constructs were linear-
ized, and digoxigenin-labeled antisense RNA and control sense probes
were generated from the template using the DIG RNA Labeling Kit
(Roche Applied Science, Basel, Switzerland). Dissected small intestinal
and liver tissue was embedded in O.C.T. medium (Tissue-Tek, Sakura
Finetek Europe B.V., The Netherlands). Ten μm sections were cut and
mounted on Super Frost Plus slides (Electron Microscopy Sciences,
Hatﬁeld, PA). Sections were post-ﬁxed in 4% (w/v) paraformaldehyde
in phosphate-buffered saline (PBS; 4 °C, 10 min), acetylated for
10 min (acetic anhydride, 0.25%; Sigma-Aldrich) and hybridized with
digoxigenin-labeled probes overnight at 62 °C. ISH was carried out as
described previously [40]. Whole-mount ISH was performed according
to the protocol of Cepko and Tabin (http://genepath.med.harvard.edu/
~cepko/protocol/ctlab/ish.ct.htm).
2.5. Isolation of intestinal crypt cells and hepatocytes,
ﬂuorescence-activated cell sorting (FACS)
Crypts from the proximal part of the small intestine of Lgr5-EGFP-
IRES-CreERT2 mice were isolated according to the protocol published
previously [41]. Single-cell suspension was obtained upon incubation of
fresh crypts with dispase I (0.8 mg/ml, 10 min at 37 °C; Sigma-Aldrich)and passing the resulting suspension through 70-μm strainer (Fisher
Scientiﬁc, Waltham, MA). Cell suspension was stained by biotinylated
Ulex europaeus agglutinin I (UEA I) (Vector Laboratories, Burlingame,
CA) and streptavidin-PE-Cy7 (BD Biosciences, Mississauga, ON). Hepato-
cytes were isolated from perfused liver of Nkd1-CreERT2+/Rosa26R-
EYFP mice as described previously [42]. The animals were injected twice
(with 24-hour interval between injections) with tamoxifen (1 mg in
100 μl of corn oil per dose) and utilized the next day upon the second
injection.
2.6. RNA isolation and reverse-transcription quantitative polymerase chain
reaction (qRT-PCR)
Total RNA was extracted from tissues or sorted cells using RNAeasy
MiniKit with DNase treatment (Qiagen, Hilden, Germany) following the
manufacturer's instructions and reverse transcribed using MAXIMA
reverse transcriptase (Thermo Fisher Scientiﬁc, Waltham, MA). The
LightCycler 480 apparatus and SYBR Green I Master Mix (Roche Applied
Science) were employed for qRT-PCR. Primers are listed in Supplementa-
ry Table S1.
2.7. Collection and analysis of human colorectal lesions
The study was approved by the Clinical and Experimental Medicine
and the Thomayer University Hospital Research Ethics Committee and
the Ethics Committee of the Third Faculty ofMedicine, Charles Universi-
ty in Prague. Processing and histopathological evaluation of samples of
35 precancerous and 20 malignant lesions of colorectal tissue were de-
scribed in full detail previously [6]. Brieﬂy, genomic DNA and total RNA
was isolated from tumor segments and matched healthy mucosa. RNA
was reverse transcribed and used for qRT-PCR analysis; PCR reactions
were run in triplicates with two negative controls (RT reactions in
which reverse transcriptase was omitted). Mutational analysis of the
APC gene was performed with genomic DNA extracted from CRC speci-
mens only. To obtain relative expression levels (-ΔCp) (Cp indicates the
crossing point value), individual Cp valueswere normalized by geomet-
ric average of internal housekeeping genes β-ACTIN (ACTB),UBIQUITIN B
(UBB) and AXIN1 (premalignant lesions of the colon), or using ACTB as a
sole reference gene (CRC-derived samples). Differential expression was
examined by non-parametric Wilcoxon's rank-sum test. In addition,
the individual background of the patients was encompassed in a
REML-ﬁtted linearmodel, described by the formulaΔCp ~ patient+ tis-
sue/(stage * APC mutation) for CRC specimen and ΔCp ~ patient +
tissue_stage in cases of precancerous lesions, respectively. Biopsies of
surrounding non-tumor tissue constitute a single group (ΔΔCp) in
both collections. In corresponding ﬁgures and tables, the number of
asterisks represents statistically signiﬁcant changes with the following
P values: *P b 0.05, **P b 0.01, and ***P b 0.001. All analyses were per-
formed in R language. Primer sequences are listed in Supplementary
Table S1.
2.8. Collection and analysis of human hepatic lesions
Neoplastic liver tissues were obtained from 28 consecutive patients
at the time of surgical resection performed at the Transplant Surgery
Department of the Institute for Clinical and Experimental Medicine.
Collection of clinical samples was accomplished in concordance with
the standards and approved by the Institute for Clinical and Experimen-
tal Medicine and Thomayer University Hospital Research Ethics Com-
mittee; all study subjects signed the informed consent. The paired,
non-tumor tissue specimens were used as controls. Histopathology
was scored in hematoxylin and eosin stained sections by two indepen-
dent pathologists; clinical characteristics are given in Supplementary
Table S2. Diagnoses of HCC were predominant within the cohort. Total
RNA was puriﬁed using the RNeasy Mini kit in automated QIAcube ex-
tractor (Qiagen). Reverse transcription was performed with 250 ng of
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supplied with 25 ng/μl oligo(dT)18 primers (Thermo Scientiﬁc). PCR
reactions were run in triplicates using Light Cycler 480. Relative expres-
sion levels (-ΔCp) were obtained upon normalization by geometric
average of internal housekeeping genes ACTB and UBB. To detect differ-
ences in expression, we employedWilcoxon's rank-sum test and, in addi-
tion, the linear model (REML) described by the formula ΔCp ~ patient +
tissue_ﬁbrosis score. Statistical signiﬁcance levels were set identically to
CRC samples.
2.9. CTNNB1 mutation analysis in HCC
Genomic DNA was puriﬁed from snap-frozen samples of tumor and
matched surrounding tissue using DNeasy Blood & Tissue Kit
(Qiagen). Exon 3 of CTNNB1, including intron-exon boundaries,
was ampliﬁed using gene-speciﬁc primers: forward: 5′taatac
gactcactatag TGCTTTTCTTGGCT GTCTTTCAG 3′; reverse: 5′tgaaa
cagctatgaccatgTCCACAGTTCAGCATTTACCTAAG 3′; overhang se-
quences corresponding to universal sequencing primers T7 and RP,
respectively, are given in lowercase letters. Each fragment was di-
rectly sequenced from both sides using the BigDye® Terminator
v3.1 cycle sequencing kit and ABI 3130 Genetic Analyzer (Applied
Biosystems, Life Technologies, Prague, Czech Republic).
2.10. CRC and HCC datasets obtained from The Cancer Genome Atlas
(TCGA)
CRC [TCGA_COADREAD; 154 cases of colon cancer (dataset COAD-
TP); 73 cases of rectal cancers, (dataset READ-TP)] [18] and HCC
(TCGA_LIHC; 197 cases) datasets were downloaded from the Broad
Institute using the utility ﬁrehose_get (http://gdac.broadinstitute.org,
Broad Institute/Massachusetts Institute of Technology, USA) on
July 18, 2014. RNA-seq data were extracted from the archive
“gdac.broadinstitute.org_COADREAD.Merge_rnaseqv2__illuminaga_
rnaseqv2__unc_edu__Level_3__RSEM_genes_normalized__data.Level_
3.2014061400.0.0” (CRC) and “gdac.broadinstitute.org_LIHC.Merge_
rnaseqv2__illuminahiseq_rnaseqv2__unc_edu__Level_3__RSEM_
genes_normalized__data.Level_3.2014061400.0.0” (HCC). Mutation
data were obtained from the archive: “gdac.broadinstitute.org_Fig. 1. Nkd1mRNA is enriched in mouse intestinal tumors. (A) ISH of Axin2 and Nkd1mRNAs in
Axin2 was also detected in lower parts of the crypts (red arrow). (B) Conditional deletion of t
Villin-CreERT2+/ApccKO/cKO mice obtained at day 0 (D0) and day 4 (D4) after tamoxifen admi
(C) Quantitative RT-PCR analysis of total RNA isolated from crypts at D0 and D4. The results w
was also included in the test. The expression level of a given gene in the crypt cells at D0 wasCOADREAD.Mutation_Packager_Calls.Level_3.2014061400.0.0” (CRC)
and “gdac.broadinstitute.org_LIHC.Mutation_Packager_Calls.Level_
3.2014061400.0.0” (HCC). Clinical data were retrieved from the ﬁles:
“gdac.broadinstitute.org_COADREAD.Merge_Clinical.Level_1.201406
1400.0.0/COADREAD.clin.merged.txt” (CRC) and “gdac.broadinstitute.
org_LIHC.Merge_Clinical.Level_1.2014061400.0.0/LIHC.clin.merged.txt”
(HCC). No further processing was applied to the data. In CRC datasets
only samples classiﬁed as colon cancer (COAD) and with a determined
mutation status of the APC gene (104 cases) are presented. DNA meth-
ylation data were retrieved from the ﬁle: “gdac.broadinstitute.org_
COADREAD.Merge_methylation__humanmethylation450__jhu_usc_
edu__Level_3__within_bioassay_data_set_function__data.Level_3.2014
061400.0.0”. Only those data subsets were analyzed that had both ex-
pression and methylation data available (366 cases). Positions of the
CpG-islands predicted by the algorithm of Wu and colleagues [43]
were obtained from the ﬁle: “http://rafalab.jhsph.edu/CGI/model-
based-cpg-islands-hg19.txt” (accessed on September 8, 2014). North
and south shores (N/S-shores) were deﬁned as chromosomal regions
ﬂanking the corresponding CpG island 2 kb upstream or down-
stream, respectively. North/south shelves (N/S-shelves) were
deﬁned as chromosomal regions ﬂanking the shores further 2 kb up-
stream/downstream [44]. Base 2 logarithm of fold change (logFC) of
NKD1 expression intensity between tumor samples and the median of
available normal tissue samples was determined. The CRC samples were
clustered according to methylation β-values (methylated/overall intensi-
ty) for the probes assigned to the NKD1 gene (InﬁniumHumanMethyl-
ation 450 array, Illumina). All analyses were performed in the R
environment.3. Results
3.1. Nkd1 expression marks Apc-deﬁcient intestinal tumors in the mouse
To analyze Nkd1 expression in mouse tumors we performed ISH
using specimens obtained from Min mice. These mice (designated
Apc+/Min) harbor a nonsense mutation in the coding region of the Apc
gene and all adult animals develop numerous Apc-deﬁcient polyps
that progress to malignancy [34]. Nkd1 mRNA was clearly detected in
the small intestinal tumors; nevertheless, we did not observe anysmall intestinal tumors (black arrows) of Apc+/Min mice. In the healthy part of the tissue
he Apc allele results in crypt hyperplasia. Hematoxylin-stained sections of the jejunum of
nistration. Hyperproliferative crypts are indicated by red arrowheads. Scale bar: 0.1 mm.
ere normalized to Ubiquitin B (Ubb) mRNA levels; another housekeeping gene, β-actin,
arbitrarily set to 1. Error bar: standard deviation (SD).
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Axin2, which was clearly enriched not only in tumors, but also at the
bottom of the intestinal crypts (Fig. 1A). To conﬁrm that Nkd1 expres-
sion is directly connected to the loss of Apc we employed animals har-
boring conditional alleles (cKO) of this tumor suppressor. Cre-
mediated excision of theﬂoxed exon 14 in ApccKO/cKOmice results in pro-
duction of a truncated polypeptide related to nonfunctional Apc protein
produced inApc+/Minmice [37]. TheApc gene inactivationwas performed
in Villin-CreERT2+/ApccKO/cKO mice expressing tamoxifen-regulated Cre
enzyme throughout the epithelia of the gastrointestinal tract [38]. As ex-
pected, robust hyperplasia of the small intestinal and colonic crypts was
observed several days upon tamoxifen administration (Fig. 1B and data
not shown). Quantitative RT-PCR analysis of crypt cells isolated from an-
imals prior and four days after tamoxifen treatment showed more than
18- and 20-fold increase in the Nkd1 mRNA levels in the Apc-deﬁcient
small intestine and colon, respectively. Wnt signaling target genes
Axin2, Lgr5, and Troywere also upregulated. In contrast, transcription of
Olfm4, amarker of small intestinal stem cellswhich is not driven by active
Wnt signaling [7], was slightly elevated in the hyperproliferative crypts
isolated from the small intestine and not from the colon (Fig. 1C).
3.2. Nkd1 is produced in theWnt-responsive areas of the small intestine and
liver
Next we analyzed the distribution of Nkd1 in the healthy gut tissue.
Since the localization of Nkd1mRNA and protein using ISH or immuno-
histochemical stainingwas inconclusive, we used transgenesis to follow
the expression pattern of the gene. BAC carrying the mouse Nkd1 locus
was employed to generate Nkd1-CreERT2 transgenic mice. In the BAC-
based construct, cDNA encoding tamoxifen-inducible Cre enzyme was
inserted into the second exon of the Nkd1 gene. The insertion is in
frame with the translation start codon located in the preceding exon
(Fig. 2A). The activity of CreERT2 recombinase produced from the
Nkd1-CreERT2 BAC transgene was visualized in embryos derived from
crossing Nkd1-CreERT2 and Rosa26R mice. Rosa26R animals express
bacterial β-galactosidase (LacZ) mRNA from the ubiquitously active
Rosa26 allele. The mRNA is not translated unless a transcriptional
blocker ﬂanked by two loxP sites is excised by Cre [35]. Developing em-
bryos removed frompregnant females one day after tamoxifen injection
were used to stain the LacZ-expressing tissue. Importantly, the expres-
sion pattern of Nkd1-CreERT2 visualized by the chromogenic X-gal sub-
strate phenocopied the sites of expression of endogenous Nkd1mRNA
obtained by whole-mount ISH (Fig. 2B). Furthermore, the sites of the
CreERT2 activity were in agreement with the previously described
Nkd1 expression pattern [31].
Subsequently, adult Nkd1-CreERT2+/Rosa26R mice were injected
with a single dose of tamoxifen and sacriﬁced at several time points
later. In the gastrointestinal (GI) tract, Cre-mediated recombination
was the most efﬁcient in the duodenum and jejunum, much less effec-
tive in the ileum, and virtually no staining was observed in the colon
(Fig. 2C). Since we [6] and others [45] observed that Cre-mediated re-
combination is less efﬁcient in the distal parts of the GI tract, we sup-
posed that the observed variability in LacZ staining was caused by the
inefﬁcient recombination of the ﬂoxed blocker rather than heteroge-
neous expression of Nkd1. Therefore, the histological analysis was per-
formed using specimens obtained from the proximal part of the small
intestine. One day after the Cre induction, cells producing LacZ were lo-
cated in the lower parts of the crypts (Fig. 2D). Twodistinct staining pat-
ternswere observed seven days after the recombination. Some of “blue”
cell clones started to extend along thewhole crypt axis. However, other
clones separated from the crypts and moved as a stripe of cells on the
villus, indicating that the recombined cell was possibly a TA cell. Finally,
three weeks after recombination, continuous “ribbons” of labelled cells
emanating from the crypts and reaching the top of the villi were ob-
served. In addition, blue cells were also found at the bottom of the
crypts, i.e. in the positions where mature Paneth cells are localized(green arrow in Fig. 2D). Importantly, Nkd1-CreERT2-expressing cells
differentiated into all major cell lineages present in the small intestine
(Fig. 2E). The recombined clones persisted in the small intestine for
more than two months, conﬁrming that besides Paneth and TA cells
some CreERT2-positive cells are indeed ISCs (not shown). To verify
that the Nkd1-CreERT2 activity mimics expression of endogenous
Nkd1, crypt cells obtained from Lgr5-EGFP-IRES-CreERT2 mice were
sorted and analyzed using qRT-PCR. Lgr5-IRES-EGFP-CreERT2 animals
express enhanced green ﬂuorescent protein (EGFP) from the Lgr5
locus, and therefore the EGFP protein can be used as a surrogatemarker
of ISCs [5]. Besides EGFP ﬂorescence, cell labeling with UEA I lectin was
applied. The lectin binds proteoglycan residues on the surface of secre-
tory cell lineages including Paneth cells and their precursors. Crypts iso-
lated from the jejunum were used for the sorting procedure since this
part of the small intestine contains only a minimal count of UEA I-
positive goblet cells [46]. The highestNkd1 expression (when compared
to TA cells negative for UEA and GFP) was detected in mature Paneth
cells (phenotype: UEA+GFP-cryptidines+) and Lgr5+ ISCs (UEA-GFP+-
EphB2+), although expression of cryptidines in the latter population
indicated that we did not obtain a homogenous cell population. Inter-
estingly, high levels of Nkd1mRNA were also detected in putative pro-
genitors of the Paneth cell lineage that are positive for UEA and GFP,
and produce Lgr5 and cryptidins as well [46]. The result was consistent
with the frequency of blue cells detected by immunohistochemical
staining of crypts in Nkd1-CreERT2+/Rosa26R mice one day after ta-
moxifen administration (Fig. 2G).
Since previous reports indicated Nkd1 expression in pericentral
hepatocytes [31], we followed the Nkd1-CreERT2 activity in adult liver
tissue. One day after tamoxifen administration, X-gal staining was de-
tected in hepatocytes surrounding the putative central vein (Fig. 3A).
The identity of LacZ-positive cells was subsequently conﬁrmed by co-
stainingwith an antibody recognizingGS, a robustmarker of pericentral
hepatocytes (Fig. 3B). Additionally, we intercrossed Nkd1-CreERT2 ani-
mals with Rosa26R-EYFP reporter mice that express enhanced yellow
ﬂuorescent protein (EYFP) instead of LacZ from the Rosa26 locus [36].
We performed gene expression proﬁling of total RNA isolated from
EYFP-positive and EYFP-negative hepatocytes sorted from these mice.
The analysis conﬁrmed that endogenous Nkd1 mRNA is robustly
enriched in EYFP+ cells along with the perivenous hepatocyte-speciﬁc
genes GS, Lect2, and Oat. In accordance with the literature, these cells
also produce increased levels of Axin2mRNA [15]. Apc and the “house-
keeping” gene glyceraldehyde-3-phosphate dehydrogenase (GAPHD) did
not show any differential distribution among the sorted cell popula-
tions; however, the periportal Pck1 gene displayed an inverse expres-
sion pattern to the perivenous genes, conﬁrming the quality of the
sorting procedure (Fig. 3C).
3.3. Elevated levels of NKD1 mRNA in sporadic premalignant lesions of the
colon and in CRC
As a next step, we examined the expression pattern of human NKD1
in tumors arising in the gut. In dysplastic premalignant stages of CRC,
we observed robust upregulation of NKD1 expression. The increase in
NKD1mRNA abundance showed an ascending tendency as the lesions
progressed towards more advanced phenotypes. In contrast, in hyper-
plastic polyps NKD1 transcription was signiﬁcantly decreased when
compared to thematched healthymucosa (Fig. 4A). In CRC the elevated
NKD1 expression occurred irrespective of the APCmutational status and
hence resembled deregulation of LGR5 (Fig. 4B) [6].
To explore the alterations in NKD1 transcription in a larger panel of
CRCs, we interrogated relevant datasets from TCGA (227 specimens in
total) [18]. The analysis was less straightforward, since the expression
data obtained from healthy matched tissue were not accessible from
these datasets. Intestinal cancers were stratiﬁed according to disease
progression, and subsequently, the tumors were further subdivided
using the classiﬁcation system associated with the cellular phenotype
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mRNA was enriched (similarly to AXIN2) in microsatellite stable
(MSS) lesions [when compared to lesions displaying low (MSI-L) or
high (MSI-H) microsatellite instability (MSI)]. Moreover, in both early
and advanced CRCs theNKD1 transcriptwas abundant in the progenitor
(“TA”) type of tumors (Supplementary Fig. S1).
3.4. NKD1 transcription indicates HCC displaying aberrant Wnt signaling
The NKD1 expression was analyzed in 28 neoplastic liver tissues ob-
tained at the time of surgery. Paired, non-tumor tissue specimens were
used as controls. Recently, Lachenmayer and colleagues employed ex-
pression data of 642 HCCs to deﬁne two classes of HCC displaying dys-regulation of theWnt pathway. The “Wnt class” is characterized by nu-
clear accumulation of β-catenin and upregulation of liver-speciﬁc Wnt
signaling target genes. The “Wnt-TGFβ” class is deﬁned by expression
of a different set of genes (see further) regulated by Wnt signaling
[25]. In the initial analysis we observed a clear separation of a fraction
of the HCC samples into the Wnt class that was established by simulta-
neous upregulation of AXIN2, EPHB2 and GS. However, we did not ob-
serve any clustering of HCCs to the Wnt-TGFβ class as examined by
transcription levels of the PLAU, MMP7, SALL1 and RUNX2 genes (not
shown). Thus, we stratiﬁed the HCC samples into subgroups deﬁned
by the Wnt-signature only. We employed the MCLUST algorithm [48]
to group the samples according to their AXIN2, EPBH2, and GS Cp values.
The algorithm identiﬁed four clusters, three of which showed low and
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small cluster sizes, we merged the Wnt signature-negative clusters
into a single class and subsequently obtained two classes of HCC desig-
nated “HCC” and “HCC_Wnt” (Supplementary Fig. S2). An alternative
clustering method, partitioning around medoids (with k = 2), resulted
in virtually identical grouping (not shown). To further validate the re-
sult, we used the algorithm to predict the class of all other samples,
i.e. healthy liver parenchyma, precancerous tissues, cholangiocellular
carcinoma, and other than HCC liver neoplasia, which we expected to
be negative for the Wnt-signature. Indeed, all these samples were cor-
rectly classiﬁed outside of the HCC_Wnt class (not shown). Finally, we
analyzed the CTNNB1 gene mutation status in genomic DNA obtained
from all liver samples. The exon 3 sequence encoding amino acid resi-
dues regulating β-catenin protein stability was used for the analysis.
Missense mutations in codons for regulatory serines/threonines (or in
codons closely adjacent to these residues) were found in 11 HCCs;
nine of these tumors were assigned to the HCC_Wnt class (Supplemen-
tary Table S3). Consistently, transcription levels ofNKD1were positively
correlated with expression of the genes deﬁning the HCC_Wnt class
(AXIN2, EPHB2, andGS), aswell aswith additional target genes of canon-
icalWnt/β-catenin signaling LGR5 and TROY. In contrast, transcription of
the paralogousNKD2 gene, which is not regulated by theWnt pathway,
was not elevated in specimens assigned to the HCC_Wnt class (Fig. 5).
Next, we analyzed relevant HCC datasets from TCGA (197 speci-
mens). The expression levels of the Wnt-signature genes AXIN2,
EPBH2, and GS and the MCLUST algorithm were employed to group
the HCC specimens. The algorithm identiﬁed three clusters of HCCs des-
ignated HCC_1 (12 samples), HCC_2 (148 samples), and HCC_Wnt (37
samples) (Supplementary Fig. S3). Additionally, we employed genomic
DNA sequencing data to determine theAPC, AXIN1/2, and CTNNB1muta-
tional status (mutations were classiﬁed according to references [49,
50]). In the examined tumors APC was compromised in 3%, AXIN1
in 5%, and AXIN2 in 2% cases. In contrast, mutations activating CTNNB1
occurred in 26% of specimens. Consistent with other studies [51],
nonsynonymous gene alterations in either the AXIN1 or APC tumor
suppressors and CTNNB1were mutually exclusive, with only one speci-
men displaying concurrent oncogenic mutations in the CTNNB1 exon 3
together with disruption of AXIN2 (not shown). Since the HCC TCGA
dataset contains exome sequencing data, we utilized the mutational
status of the APC, CTNNB1, and AXIN1/2 genes to divide all specimens
to three mutation groups (designated “Wnt_WT”, “Wnt_MUT”, and
“Other”). As expected, HCC_Wnt class-speciﬁc genes AXIN2, EPHB2
and GS were robustly overexpressed in the Wnt_MUT group (sample
count 38) deﬁned by CTNNB1 (activating) and APC (inactivating) muta-
tions (Supplementary Fig. S4). Importantly, in the TCGA HCC1 samplesFig. 2. Tracking Nkd1 expression using Nkd1-CreERT2 BAC transgenic mice.(A) Schemes depict
transgenic mice. CreERT2 was inserted into the second coding exon of the Nkd1 gene of bacte
located in the Nkd1 ﬁrst exon. The non-coding or translated regions are indicated by empty and
RGBpolyA, a polyA signal derived from the rabbitβ-globulin gene; KanR, the kanamycin resista
cassette was excised from recombinant BAC using Flp recombinase and FRT sites (violet semicir
mouse embryo at embryonic day (E) 14.5 using an antisense probe againstNkd1 (left image)wi
Nkd1-CreERT2+/Rosa26R embryos obtained at the same developmental stage (right). Tamoxife
day later. cb, cerebral plate; dﬂ, distal forelimb; dhl, distal hindlimb drg, dorsal root ganglion; ee
ofwhole-mount staining of LacZ in different anatomical parts of the intestine of Nkd1-CreERT2+
ileum; col, colon. (D) Lineage tracing in the duodenum of Nkd1-CreERT2+/Rosa26R mice. The
ministration. The slides were counterstained with nuclear red. One day upon tamoxifen admini
whereas threeweeks later cellular clones formed blue ribbons extending from the crypts to the
bottom (green arrow in the left image). (E) Double labeling shows that blue cells express mar
PAS), and Paneth (anti-lysozyme) cell lineages. (F) Expression of endogenous Nkd1 in cell popu
bottom. Left, diagram of the sorting procedure using crypt cells isolated from the proximal hal
obtained representing ISCs (GFP+), putative precursors of Paneth and enteroendocrine cell line
of sorted crypt cell populations. Cp values were normalized to Ubb. Means relative to values obt
14/15. (G) Distribution of LacZ-positive cells in the crypts of Nkd1-CreERT2+/Rosa26R mice on
intestine in two mice were counted. Results are depicted as means with SDs. The cell positions
cells occupy crypt positions “0” and “1”, and putative Paneth cell progenitors position “2”. ScalNKD1 transcription was also positively correlated with AXIN2, EPBH2,
and GS, and, furthermore, NKD1 mRNA was signiﬁcantly enriched in
the Wnt_MUT group (Fig. 6A). Interestingly, in ﬁve HCC specimens
that were assigned to the HCC_Wnt expression class, no oncogenic mu-
tations in APC, CTNNB1, and AXIN1/2 were detected (one sample was
assigned to the mutational subgroup “Other” and four other HCCs to
the subgroup Wnt_WT) (Supplementary Table S4). Careful scrutiny of
genomic DNA from the tumor in the “Other” group revealed that this
lesion harbors a missense mutation (c.G417T/p.L139F) in exon 4 of
the CTNNB1 gene that possibly compromises the structural integrity of
the ﬁrst armadillo repeat of β-catenin. Consequently, the alteration
might lead – by inhibiting phosphorylations by CK1 – to β-catenin sta-
bilization and inappropriate signaling [52]. We investigated the molec-
ular background of four other samples from the Wnt_WT mutation
group. Interestingly, we detected increased levels of LGR5 in these spec-
imens. In addition, in two tumors, copy-number identiﬁed ampliﬁcation
of the R-spondin 2 (RSPO2) gene that encodes the LGR5 ligand and func-
tions as an extracellularWnt agonist (Fig. 6B; HCCswith RSPO2 ampliﬁ-
cation are indicated as orange and violet triangles) [53].
We used data deposited by the TCGA consortium to analyze muta-
tions or genomic rearrangement of the NKD1 locus in cancer tissue.
Previous reports identiﬁed the NKD1mutations within CRCs displaying
MSI [54]. However, the coding region of NKD1 in the corresponding
TCGA dataset showed that the gene was modiﬁed only marginally,
with one nonsense (p.R294X), one missense (p.P230L), and one silent
mutation (p.L142L) detected within CRC samples and one silent muta-
tion (p.C248C) found in rectal cancers, respectively. In addition, TCGA
CRC samples were explored using the COSMIC interface (http://
cancer.sanger.ac.uk/cancergenome/projects/cosmic/). The open read-
ing frame of NKD1 was found to be altered by one silent (p.G312G),
one missense mutation (p.A374T) and one in-frame deletion
(p.K104delK). Of note, neither of the missense mutations affect the
NKD1 EFX domain presumably required for the interaction with DVL
proteins [27]. Moreover, unlike reported [54], the integrity of the
NKD1 exon 10 poly(C)7 stretchwas impaired in a single case. Moreover,
the NKD1 genomic region was never subjected to signiﬁcant ampliﬁca-
tion or deletion (data not shown). In linewith CRC,mutational inactiva-
tion of NKD1 is rare in HCC, with one p.P349L substitution detected
within the HCC TCGA dataset and similarly, two NKD1missense muta-
tions (p.R31P and p.K116R) recorded within COSMIC data survey (827
samples).
Finally, themethylation status of theNKD1 locus in 366 CRC samples
from the TCGA dataset
was analyzed and correlated to theNKD1 transcription level.Where-
as the CpG island (and adjacent loci) proximal to the NKD1 promotering the BAC clone RP23-301N2 harboring the Nkd1 locus and generation of Nkd1-CreERT2
ria using homologous recombination. The insertion is in frame with the translation start
black boxes, respectively. a,b, Nkd1 sequences employed for homologous recombination;
nce gene; pBla,β-lactamase promoter. Prior to pronuclear injection, the bacterial resistance
cles) ﬂanking the cassette. (B) Comparison of thewhole-mount hybridization ofwild-type
th the activity of CreERT2 recombinase produced from theNkd1-CreERT2 BAC transgene in
nwas injected intraperitoneally into pregnant females and the animalswere sacriﬁced one
, ear;ma, maxilla; mg, mammary gland primordium; vi, vibrissae. (C) Stereoscopic images
/Rosa26Rmice six days after tamoxifen administration. duod, duodenum; jej, jejunum; ile,
LacZ activity was detected in histological specimens at indicated days after tamoxifen ad-
stration the bottom parts of the crypts were labelled (black arrowheads in the left image),
villi (right image). In addition, the tissue contains labelled Paneth cells residing at the crypt
kers of enteroendocrine (visualized by anti-chromogranin A staining), goblet (positive for
lations sorted from the intestinal crypts is conﬁned to the cell types localized at the crypt
f of the small intestine of three Lgr5-EGFP-IRES-CreERT2 mice. Four cell populations were
ages (GFP+UEA+), mature Paneth cells (GFP-UEA+), TA cells (GFP-UEA-). Right, qRT-PCR
ained in GFP-UEA- cells are presented with corresponding SDs. Crypt, cryptidins 1/3/6 – 12/
e day after tamoxifen administration. Four hundred crypts in proximal parts of the small
are indicated in the scheme in the inset: Paneth cells (“P”) are depicted in red, CBC stem
e bar: 2 mm (B), 5 mm (C), 0.1 mm (D), 5 μM (E).
Fig. 3. Nkd1 transcription is zonated to the perivenous hepatocytes. (A) Left, whole-mount staining of LacZ in the adult liver of Nkd1-CreERT2+/Rosa26R mice one day after tamoxifen
administration. Right, histochemical staining detects the LacZ activity in hepatocytes surrounding the putative centrilobular veins [(cv); red arrow]; periportal hepatocytes in close proximity
to the portal space [(ps); black arrow] are LacZ negative. The specimen was counterstained with nuclear red. Scale bar: 4 mm (left image), 0.3 mm (right image). (B) Immunohistochemical
co-localization of LacZ (blue color) and anti-GS (brown color) staining. The specimen was counterstained with hematoxylin. Scale bar: 0.3 mm. (C) Left, whole-mount ﬂuorescent image of
the Nkd1-CreERT2+/Rosa26R-EYFP liver taken four days upon tamoxifen administration. Scale bar: 0.4 mm. Right, qRT-PCR analysis of EYFP+ and EYFP- cells sorted from the Nkd1-CreERT2+/
Rosa26R-EYFP liver. The resultswere normalized toUbbmRNA levels. The expression level of a given gene in EYFP- cellswas arbitrarily set to 1 (red line). Error bar: SD. Notice the enrichment of
Nkd1mRNA along with other pericentral hepatocyte genes Axin2, GS, Lect2, and Oat. In contrast, Apc and GAPDH genes are not zonated and portal-speciﬁc Pck1 displays a complementary
expression pattern to the perivenous hepatocyte genes.
252 J. Stancikova et al. / Cellular Signalling 27 (2015) 245–256was hypomethylated in the majority of CRCs, the distal CpG island was
heavilymethylated. In concordancewith previously published data [44]
, differential methylation of the CpG island and adjacent “shores” (forFig. 4.NKD1 expression is increased during colorectal cancerogenesis. (A) Relative expression leve
ing normalization of Cp values by geometric average of internal housekeeping genes ACTB, UBB
low-grade dysplasia (LGD) and high-grade dysplasia (HGD) subgroups. (B) Relative levels of NK
ΔCp's.Malignant lesionswere subdivided to distinct subgroupswith respect to the APCmutation s
of differential expression in the given groups was examined by nonparametricWilcoxon's rank-su
individual background of the patients, tissue type, histopathology, APCmutation status (CRC spec
range of the values is given by “whiskers” above and beloweach box.Median ofΔCp values for indi
found in Supplementary Table S5 and S6, respectively. *P b 0.05, **P b 0.01, and ***P b 0.001. HMterminology see Materials and Methods) situated within 2 kb of the
transcription start site was strongly associated with transcription of
the NKD1 gene. Interestingly, the highest NKD1 mRNA levels werels ofNKD1 in colorectal polyps. Log of relative expression levels (-ΔCp)were obtained follow-
and AXIN1. Predominant histological appearance stratiﬁed the lesions to hyperplasia (H),
D1 transcript in CRCs. Cp values were normalized using ACTB as a reference gene to obtain
tatus (WT,wild-type APC;MUT,APCmutated) and disease progression. Statistical signiﬁcance
m test (solid line). Moreover, the linearmodel (REML; dashed line), which accounted for the
imens only), was applied. The boxed areas correspond to the second and third quartiles; the
vidual categories is depicted as the red line. Statistical data accompanying Fig. 4A and B can be
, matching healthy mucosa; P, polyp; T, tumor.
Fig. 5.NKD1 transcription is elevated in theWnt class of HCCs. RelativemRNA abundance of the indicated genes in liver tumors andmatched surrounding tissue. For each gene, Cp values
were normalized by geometric average of the housekeeping genes ACTB and UBB (−ΔCp). The Wnt class (HCC_Wnt) was deﬁned by expression levels of AXIN2, EPBH2, and GS genes
(details are given in Supplementary Fig. S2). Two cases of cholangiocellular carcinoma constitute a separate group designated as ChCC. Additional types of liver neoplasia (adenolipoma,
focal nodular hyperplasia and metastasis of colorectal carcinoma) were merged to a single group (N). Specimens of matched surrounding parenchyma were assessed according to the degree
of ﬁbrosis as healthy (H), precancerous tissue displaying mild to moderate ﬁbrosis (PT.F0), or precancerous tissue exhibiting severe ﬁbrosis to cirrhosis (PT.F1) [73]. Statistical signiﬁcance of
differential expression in the given groups was examined by nonparametric Wilcoxon's rank-sum test (solid line). Moreover, the linear model (REML; dashed line), which accounted for the
individual background of the patients, tissue type and ﬁbrosis score, was applied. The presence of viral infection is indicated by graphical symbols [circle: virus not detected; triangle: HBV
positive; down-pointing triangle: HCV positive; lozenge: HBV + HCV positive]. Statistical analysis of ChCC samples was omitted from the image due to the small group size. Median of ΔCp
values for individual categories is depicted as the red line. Numeric values accompanying this ﬁgure are given in Supplementary Table S7. *P b 0.05, **P b 0.01, and ***P b 0.001.
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3 S-shore region (Supplementary Figure S5).
4. Discussion
The activity of the Wnt pathway undergoes complex regulation to
ensure proper functioning of signaling during development and in
adult tissue homeostasis. The regulation may occur at several levels
and includes both positive and negative feedback loops. In the intestinal
crypt, a well-established cellular system depending on Wnt signaling,
the pathway up-regulates Lgr5, a receptor for Rspos, and consequently,
the Lgr5-Rspo interaction augments the Wnt/β-catenin signaling out-
put [53]. In addition, Axin2 and Troy, two inhibitors of theWnt pathway,
are also induced by Wnt signaling [6,55]. Interestingly, mRNA levels
encoding these genes display some variations among different cellulartypes located in the crypt. Troy appears to be exclusively expressed in
ISCs [6,56]. However, Lgr5 – originally sought to be a unique stem cell
marker – is also produced in non-dividing progenitors of the Paneth
cells lineage [46]. Moreover, Axin2 expression is conﬁned to the major-
ity of cellular types located in the lower part of the crypts, i.e. ISCs,
Paneth cells and their progenitors, and TA cells [46]. According to our
lineage tracing experiments and expression analysis (Fig. 2), Nkd1 rep-
resents another negative feedback regulator ofWnt signaling displaying
relatively broad expression in the mouse crypt. Currently, it is not clear
whether the observed differences in expression proﬁles of these Wnt
pathway genes have any functional consequences. It is possible that
these differences contribute to the ﬁne-tuning of Wnt signaling. How-
ever, since targeted inactivation of any of the genes described above
has no obvious phenotype, such explanation seems unlikely. More
probably, random ﬂuctuations in gene transcription might account for
Fig. 6. NKD1 deﬁnes HCC displaying aberrantWnt signaling. (A) Left panel, expression of NKD1 in three gene expression classes of HCCs. The TCGA HCC specimens were stratiﬁed using
transcription levels of the AXIN2, EPHB2, and GS (details are given in Supplementary Fig. S3). Right panel, relative expression of NKD1 in HCC samples assigned to the individual mutation
groups. Classiﬁcation of the TCGA HCC specimens according to mutational changes in APC, AXIN1/2, and CNNB1 is given in Supplementary Fig. S4. (B) Expression of LGR5 and RSPO2 in the
HCCmutation groups. Samples assigned to theHCC_Wnt class that do not fall to theWnt_MUT group are indicated by triangles ofmatched color. Black lines indicatemedian of expression
levels for individual categories. Numerical values accompanying this ﬁgure are given in Supplementary Tables S7 and S8. *P b 0.05, **P b 0.01, and ***P b 0.001.
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. In the mouse liver, Nkd1 represents, together with Axin2 and Troy (BF
and VK, unpublished data), a robust marker of perivenous hepatocytes.
Although the involvement of Wnt signaling in liver zonation is well
established, the liver-speciﬁc Nkd1 function has not been – similarly
as in gut tissue – documented.
In a collection of human intestinal neoplasia the NKDmRNA levels
were upregulated in nearly all of the tumors irrespective of the APC sta-
tus (Fig. 4). This was seemingly surprising, since in mouse hyperplastic
crypts Nkd1 overexpression was directly linked to Apc loss. Neverthe-
less, the mutational status of APC in the panel of CRCs was based on se-
quencing of the exon 19 (NCBI nomenclature) that contains the
mutational “hot spot”, but it likely does not cover all APC mutations
[6]. Moreover, recent studies employing massive parallel sequencing
of tumor DNA indicated that gene alterations resulting in hyperactive
Wnt signaling can be found in more than 90% of CRCs [18]. Therefore,
limited knowledge of the status of theWnt pathway in (our) CRC collec-
tion can be attributed to the discrepancy betweenNkd1 expression data
obtained in themouse and in clinical samples. This explanation may in-
terpret the observed decrease in the NKD1mRNA levels in hyperplastic
polyps (Fig. 4A). According to the recent concept of the “serrated neo-
plasia pathway”, precancerous hyperplasia is linked to the development
of a separate subclass of gut tumors [58]. Serrated CRC lesions arepredominantly initiated by oncogenic BRAFmutations and do not har-
bor genetic changes that would compromise control overWnt signaling
[59].
Relevant CRC datasets obtained from TCGA did not include paired
samples of the healthymucosa, and thus we could not directly compare
the NKD1mRNA levels in tumors and normal (matched) tissue. Never-
theless, in APC-deﬁcient CRCs at early stage of progression, NKD1
transcription was higher in MSS lesions than in tumors displaying
increased levels ofmicrosatellite instability. Furthermore, upon subdivi-
sion of CRCs according to their expression signature, NKD1mRNA was
signiﬁcantly increased in the TA (progenitor) type of the tumors (Sup-
plementary Fig. S1). Whether the extent of NKD1 upregulation reﬂects
a particular mechanism of tumor initiation or mirrors the variability of
NKD1 expression in the cellular types present in the healthy colon
remains to be determined.
Although in the majority of CRCs the aberrant Wnt activity is attrib-
utable tomutations affecting intracellular components of theWnt path-
way [18], the signaling output can be augmented by epigenetic silencing
of genes encoding secreted Wnt antagonists, such as secreted frizzled-
related proteins (SFRPs) and dickkopf WNT signaling pathway inhibi-
tors (DKKs) [60–63]. Thus, integration of genetic and epigenetic chang-
es that affectmultiple steps of theWnt signal transduction likely confers
a selective advantage to tumor cells. In line with these “multiple-hit”
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observed in ovarian and gastric cancer [64,65], we investigated the
methylation status in 366 CRC samples of the TCGA dataset and exam-
ined its relation to NKD1 transcription. In contrast to other neoplasia,
loci proximal to the NKD1 promoter were unmethylated. Moreover,
NKD1mRNAwas more abundant in colorectal tumors displaying hypo-
methylation in the S-shore region located in the third intron of the
NKD1gene (Supplementary Figure S5). Strikingly, theCRC “methylome”
analysis by Irizarry and colleagues identiﬁed an identical inverse rela-
tionship between intron 3 S-shore methylation and NKD1 expres-
sion [44]. In summary, dysregulation of NKD1 in tumors is possibly
driven by as yet undescribed epigenetic mechanisms.
The etiology of HCC ismainly associatedwith alcohol abuse andHBV
andHCV infection. Consequently, HCC is rather a heterogeneous disease
and the link between aberrant Wnt signaling and HCC is less obvious
than in the cancer of the colon and rectum. Although there is no gener-
ally acceptedmolecular classiﬁcation of the disease, several recent stud-
ies identiﬁed (sub)classes of HCC. Importantly, theWnt-associated class
of HCC (approximately 20–40% of all cases) is predominantly deﬁned by
the presence of activatingmutations in the CTNNB1 gene. In contrast, al-
terations in APC, so dominant in CRC, are less frequent in HCC (2–3%)
[66]. This is rather peculiar since the APC gene represents a substantially
larger “target” than the exon 3 in the CTNNB1 gene. Of note, in hepato-
blastoma, the most frequent malignant pediatric tumor of the liver,
approximately 50% of neoplastic lesions harbor activating mutation in
CTNNB1 [67] and display elevated expression of NKD1 [68]. Neverthe-
less, since APC and CTNNB1mutations are mutually exclusive, the high
frequency of the changes in the latter gene possibly reﬂects a combina-
tion of the locus accessibility and/or presence of liver-speciﬁc mutagens
rather than any unique β-catenin-dependent role in HCC initiation or
progression.
The gene expression signature of three Wnt signaling target genes,
AXIN2, EPHB2, and GS, was used to stratify HCCs to the β-catenin-
dependent “HCC_Wnt” class. Although we were unable (probably due
to the limited number of specimens in our experimental collection) to
separate the rest of the samples to other classes as described previously
[25], the NKD1 expression proﬁle ﬁtted well to the “HCC_Wnt” class. In
agreementwith these results, bioinformatic analysis of theHCC datasets
obtained from TCGA conﬁrmed that AXIN2, EPHB2, GS, and NKD1 repre-
sent robust markers of the HCC_Wnt class. Interestingly, not all speci-
mens from this class harbored mutations in the APC, AXIN1/2, and
CTNNB1 genes. Interestingly, we observed ampliﬁcation of the RSPO2
locus in two of the samples (out of four in total). This is in accordance
with recent data indicating that the ampliﬁcation of theRSPO genes rep-
resents a frequent event in HCC (up to 25%) [51–66]. Increased produc-
tion ofRSPO ligands has been observed in CRC as anoncogenic “by-pass”
mechanism that circumvents intact APC [69]. Collectively, the membra-
nous inputs may contribute to liver tumorigenesis in a manner analo-
gous to signaling circuits described in CRC. Finally, seven samples
assigned to the Wnt_MUT group did not display the Wnt-dependent
expression signature. Since all these samples carried “likely onco-
genic mutations” (LOMs) in exon 3 of the CTNNB1 (Supplementary
Table S4) that do not change the regulatory serine/threonine residue,
we presume that these mutations are “passenger”without any effect on
the β-catenin stability.
Simultaneous inactivation of APC and AXIN2 or APC andNKD1 occurs
in exceptional cases only. Since sustained expression of AXIN2 andNKD1
is typical of APC-deﬁcient tumors, we speculate that the function of
these Wnt pathway inhibitors might be strongly favored to keep the
Wnt pathway activity “optimal” for tumor growth [70,71]. This con-
clusion is in accordance with recent results of Barrry and colleagues
demonstrating that another DVL interacting partner, yes-associated pro-
tein 1 (YAP1), limits aberrant Wnt signaling and that YAP1-deﬁciency
leads to highly aggressive undifferentiated CRCs or results in Wnt hyper-
sensitivity during intestinal regeneration [72]. Interestingly, YAP1 re-
stricts Wnt signaling independently of the β-catenin destructioncomplex by suppressing nuclear translocation of Dvl. Thus, we propose
that in concordance with the “passive antagonist” model [32], Nkd1
might directly inﬂuence the nuclear Dvl function in cells displaying hy-
peractive Wnt signaling.
In summary, despite its unclear molecular function, NKD1 can serve
as a reliable marker of intestinal and liver tumors that display aberrant
Wnt/β-catenin signaling.
5. Conclusion
Mutations in genes encoding components of the Wnt/β-catenin
pathway that result in aberrant activation of the signaling are undoubt-
edly linked to the onset of intestinal cancer. In contrast, the etiology of
liver cancer is heterogeneous and frequently linked to viral infection. Al-
though several recent studies aimed to identify subclasses of HCC, there
is no generally accepted molecular classiﬁcation of the disease. In the
present study we employed a negative feedback regulator of Wnt sig-
naling, Nkd1, as a marker of active Wnt signaling in the intestine and
liver and in tumors originating from these organs. Our results provide
evidence that NKD1 can be utilized to distinguish a class of HCC linked
to aberrant Wnt signaling.
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